Vatta Adriano F, Young David R, King Vickie L, Myers Melanie R
Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI, 49007, USA.
Young Veterinary Research Services, 7243 East Avenue, Turlock, CA, 95380, USA.
Vet Parasitol. 2019 Jun;270 Suppl 1:S58-S63. doi: 10.1016/j.vetpar.2019.05.012. Epub 2019 Jun 3.
The efficacy of three consecutive monthly treatments with a novel topical product (Revolution Plus/Stronghold Plus, Zoetis) containing selamectin in combination with the isoxazoline, sarolaner, was compared with that of another topical isoxazoline, fluralaner [Bravecto (fluralaner topical solution) for Cats, Merck] against Ixodes scapularis ticks on cats. Twenty-four cats were ranked by pre-treatment tick counts to form groups of three and were randomly allocated to be treated with placebo, the minimum label dosage of Revolution Plus (6 mg/kg selamectin plus 1 mg/kg sarolaner) or the minimum label dosage of Bravecto for Cats (40 mg/kg fluralaner) within the groups. On Days 0, 30, and 60, each cat in the placebo and Revolution Plus-treated groups was treated topically, whereas cats in the Bravecto for Cats-treated group were treated topically once on Day 0 with fluralaner and, subsequently, these animals were treated with the placebo on Days 30 and 60 to maintain masking. Doses were calculated based on weight to provide the minimum label dosage for each product; the calculated volume of product to be administered was rounded off to the nearest 0.1 mL. The selamectin plus sarolaner-treated cats received effective dosages of 5.29-7.12 mg/kg selamectin and 0.88-1.19 mg/kg sarolaner, while the fluralaner cats received dosages of 35.21-43.16 mg/kg fluralaner. Cats were infested with approximately 50 unfed viable adult I. scapularis ticks on Days 5, 12, 26, 40, 54, 68, 82, and 88. Efficacy was assessed at 48 h after each infestation. There were no adverse reactions to any treatment during the study. The placebo-treated cats maintained adequate tick infestations throughout the study. Three monthly treatments with selamectin plus sarolaner (Revolution Plus) resulted in high and consistent efficacy against I. scapularis for up to 30 days after each treatment. Based on geometric means, efficacy was ≥99.1% at all time points assessed. Treatment with fluralaner (Bravecto for Cats) provided high and consistent efficacy of ≥99.3% up to Day 70. On Day 84, efficacy was 90.1%; however, cats from which ticks were recovered on Day 84 had received approximately 4%-12% less than the minimum dosage of 40 mg/kg fluralaner. Three consecutive monthly treatments with Revolution Plus or a single treatment with Bravecto for Cats provided >90% control of I. scapularis ticks over a 12-week time period.
将含有塞拉菌素并与异恶唑啉类药物沙罗拉纳联用的新型局部用产品(瑞倍适加强版/蚤立清加强版,硕腾公司)连续三个月每月进行一次治疗的效果,与另一种局部用异恶唑啉类药物氟虫腈(用于猫的拜宠爽[氟虫腈局部溶液],默克公司)针对猫身上肩突硬蜱的治疗效果进行了比较。根据治疗前蜱虫计数对24只猫进行排序,分成每组三只的组,并随机分配在组内接受安慰剂、瑞倍适加强版的最低标签剂量(6mg/kg塞拉菌素加1mg/kg沙罗拉纳)或用于猫的拜宠爽的最低标签剂量(40mg/kg氟虫腈)治疗。在第0天、第30天和第60天,安慰剂组和瑞倍适加强版治疗组的每只猫进行局部治疗,而用于猫的拜宠爽治疗组的猫在第0天用氟虫腈进行一次局部治疗,随后,这些动物在第30天和第60天用安慰剂治疗以维持盲法。根据体重计算剂量以提供每种产品的最低标签剂量;计算得出的待给药产品体积四舍五入到最接近的0.1mL。塞拉菌素加沙罗拉纳治疗的猫接受的有效剂量为5.29 - 7.12mg/kg塞拉菌素和0.88 - 1.19mg/kg沙罗拉纳,而氟虫腈治疗的猫接受的剂量为35.21 - 43.16mg/kg氟虫腈。在第5天、第12天、第26天、第40天、第54天、第68天、第82天和第88天,给猫感染约50只未进食的存活成年肩突硬蜱。在每次感染后48小时评估疗效。在研究期间,对任何治疗均未出现不良反应。在整个研究过程中,安慰剂治疗的猫维持了足够的蜱虫感染。用塞拉菌素加沙罗拉纳(瑞倍适加强版)连续三个月每月进行一次治疗,在每次治疗后长达30天对肩突硬蜱产生了高且一致的疗效。基于几何平均数,在所有评估时间点的疗效均≥99.1%。用氟虫腈(用于猫的拜宠爽)治疗,直至第70天提供了≥99.3%的高且一致的疗效。在第84天,疗效为90.1%;然而,在第84天有蜱虫存活的猫接受的剂量比40mg/kg氟虫腈的最低剂量少约4% - 12%。用瑞倍适加强版连续三个月每月进行一次治疗或用用于猫的拜宠爽进行单次治疗,在12周的时间段内对肩突硬蜱的控制率>90%。